SCHEMBL6307133

SCHEMBL6307133

Clc1ncc(Cl)c2[nH]cnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 4/20 0.44
DYRK1A Q13627 3/20 0.39
CSNK2A2 P19784 2/20 0.39
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.39
CSNK2B P67870 1/20 0.39
KMT2A Q03164 1/20 0.39
CSNK2A3 Q8NEV1 1/20 0.39
DPP4 P27487 2/20 0.37
AURKA O14965 2/20 0.35
DAPK3 O43293 2/20 0.35
PRKD3 O94806 2/20 0.35
MAP4K4 O95819 2/20 0.35
RET P07949 2/20 0.35
IGF1R P08069 2/20 0.35
PIM1 P11309 2/20 0.35
CLK2 P49760 2/20 0.35
GSK3A P49840 2/20 0.35
GSK3B P49841 2/20 0.35
PRKX P51817 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6307456 0.79 CSNK2A1 (0.41) CSNK2A1DYRK1ACSNK2A2MEN1RAB9A
SCHEMBL20200208 0.79 CSNK2A1 (0.41) CSNK2A1DYRK1ACSNK2A2MEN1RAB9A
SCHEMBL20399971 0.79 CSNK2A1 (0.45) CSNK2A1DYRK1ACSNK2A2MEN1RAB9A
SCHEMBL31315058 0.79 CSNK2A1 (0.41) CSNK2A1DYRK1ACSNK2A2MEN1RAB9A
SCHEMBL17253699 0.79 CSNK2A1 (0.41) CSNK2A1DYRK1ACSNK2A2MEN1RAB9A
SCHEMBL197041 0.73 CSNK2A1 (0.47) CSNK2A1DYRK1ACSNK2A2MEN1RAB9A
SCHEMBL2906446 0.73 CSNK2A1 (0.47) CSNK2A1DYRK1ACSNK2A2MEN1RAB9A
SCHEMBL30663427 0.73 CSNK2A1 (0.47) CSNK2A1DYRK1ACSNK2A2MEN1RAB9A
SCHEMBL31135882 0.71 CSNK2A1 (0.45) CSNK2A1DYRK1ACSNK2A2MEN1RAB9A
SCHEMBL16475165 0.71 CSNK2A1 (0.45) CSNK2A1DYRK1ACSNK2A2MEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040116362-A1 Novel nucleosides and related processes, pharmaceutical compositions and methods YALE UNIVERSITY 2004-06-17 US claimed
US-6960568-B2 Nucleosides and related processes, pharmaceutical compositions and methods YALE UNIVERSITY (US) 2005-11-01 US disclosed
US-20050239726-A1 Novel nucleosides and related processes, pharmaceutical compositions and methods YALE UNIVERSITY (US) 2005-10-27 US disclosed
US-20040116362-A1 Novel nucleosides and related processes, pharmaceutical compositions and methods YALE UNIVERSITY 2004-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239726-A1 Novel nucleosides and related processes, pharmaceutical compositions and methods ADAR, DCTD, ADA CSNK2A1 3461/4885DYRK1A 1157/4885CSNK2A2 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.